• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

16.17 +1.10 (+7.30%)
Delayed Quote Updated: 2:33 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,228,502
Open 15.01
Bid (Size) 16.16 (500)
Ask (Size) 16.18 (200)
Prev. Close 15.07
Today's Range 14.99 - 16.25
52wk Range 12.73 - 39.89
Shares Outstanding 70,814,462
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
October 14, 2026
Agreement marks the Company’s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
October 07, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire

Performance

52-Week Range 59.5% below 52-week high
16.17
12.7352W Low 39.8952W High
1 Week
14.441W Low 15.391W High

Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) traded between $12.73 and $39.89 over the past 52 weeks and last traded at $16.17, 59.5% below its 52-week high. Over the past week it ranged between $14.44 and $15.39.

Past 12 Months
+8.4%
+10.4%
-43.3%
-35.5%
-31.5%
-53.0%
1W +$1.25
1M +$1.52
3M -$12.36
6M -$8.89
YTD -$7.43
1Y -$18.23

RARE was -53.0% over the past year, -35.5% over six months, -31.5% year to date, +8.4% in the last week.

12 Months vs Market
RARE
-53.0%
DIA
+12.2%
SPY
+14.5%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months RARE returned -53.0% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.5%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.55× 3-mo avg
Today 2,228,502 3-mo avg 4.0M
1W
3.5M
1M
4.4M
3M
4.0M
6M
3.1M
YTD
2.8M
1Y
2.7M

RARE most recently traded 2,228,502 shares against a 3-month average daily volume of 4.0M.

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
October 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 29, 2026
From Pomerantz LLP
Via GlobeNewswire
Ultragenyx (NASDAQ:RARE) Q2 Beats Estimates, Reaffirms Guidance as Shares Rise ↗
August 04, 2026
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 22, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
September 17, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 08, 2026
From Pomerantz LLP
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
September 03, 2026
Via Chartmill
Thursday's session: top gainers and losers ↗
September 03, 2026
Via Chartmill
Gapping stocks in Thursday's session ↗
September 03, 2026
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
September 03, 2026
Via Chartmill
These stocks are moving in today's after hours session ↗
September 02, 2026
Via Chartmill
News headline image
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
September 02, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
September 01, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy ↗
August 20, 2026
Via MarketBeat
News headline image
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
August 19, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx (RARE) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights ↗
August 04, 2026
Via MarketBeat
Topics Earnings
News headline image
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
August 04, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
July 28, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
July 08, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 16.17
When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 10/20/26 02:33 PM ET
What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.15B
How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
Ultragenyx Pharmaceutical Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap